Source: Annual Congress 2004 - Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. V. Mihailovic-Vucinic, J. L. Videnovic, J. Maric-Zivkovic, V. Zugic, S. D. Filipovic (Beograd, Serbia & Montenegro). Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis. Eur Respir J 2004; 24: Suppl. 48, 4366

Member's Comments

No comment yet.

Related content which might interest you: Pentoxifylline in treatment of pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Severe lung involvement in systemic scleromyxoedema: a highly unusual finding Source: Eur Respir J 2002; 19: 976-979 Year: 2002 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 A vasomotor form of the endothelial dysfunction of the microvasculature in patients with a chronic obstructive pulmonary disease, and in combination with the pulmonary embolism Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 354s Year: 2002 Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis Source: Eur Respir J 2006; 27: 1307-1310 Year: 2006 Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation Source: Eur Respir J, 53 (3) 1801184; 10.1183/13993003.01184-2018 Year: 2019 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Systemic and pulmonary inflammation in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pathophysiology of COPD Year: 2008 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004 Pulmonary hypertension is common in end-stage sarcoidosis Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005 The comparison of the manifestation of systemic inflammation in patients with minor forms of tuberculosis and pulmonary sarcoidosis Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009